Multidisciplinary management and the future of treatment in cholangiocarcinoma

Richard Burkhart, Daniel Laheru, Joseph M. Herman, Timothy M. Pawlik

Research output: Contribution to journalArticle

Abstract

Introduction: Cholangiocarcinoma is an often lethal and relatively rare cancer that arises from the epithelial lining of the biliary tree. Disease can arise throughout the liver, at the confluence of the right and left main hepatic ducts, or as the common bile duct runs toward the ampulla of Vater. Cholangiocarcinoma has a distinct geographic variability with the greatest incidence in the Far East. Worldwide, the incidence of cholangiocarcinoma appears to be increasing.Areas covered: In this review, a comprehensive search of the peer-reviewed literature is completed to provide an update regarding the diagnostic adjuncts, clinical management, and areas of active research for this disease. There are no reliable screening tools available for clinical detection. Surgery is the only chance for cure. Chemotherapy is often used in the adjuvant setting or in patients with unresectable disease, though outcomes are generally poor. Newer approaches that include hepatic artery-based therapies and image guided radiation therapy appear to provide limited survival benefit.Expert opinion: Maximizing survival following a diagnosis of cholangiocarcinoma relies on a multidisciplinary team of experts in medical oncology, radiation oncology, surgical oncology (principally hepatopancreatobiliary surgeons), and interventional radiology.

Original languageEnglish (US)
Pages (from-to)255-267
Number of pages13
JournalExpert Opinion on Orphan Drugs
Volume4
Issue number3
DOIs
StatePublished - Mar 3 2016

Fingerprint

Cholangiocarcinoma
Image-Guided Radiotherapy
Ampulla of Vater
Common Hepatic Duct
Interventional Radiology
Radiation Oncology
Survival
Medical Oncology
Far East
Hepatic Artery
Incidence
Expert Testimony
Common Bile Duct
Biliary Tract
Therapeutics
Drug Therapy
Liver
Research
Neoplasms

Keywords

  • adjuvant therapy
  • Cholangiocarcinoma
  • neoadjuvant therapy
  • stereotactic body radiation therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Multidisciplinary management and the future of treatment in cholangiocarcinoma. / Burkhart, Richard; Laheru, Daniel; Herman, Joseph M.; Pawlik, Timothy M.

In: Expert Opinion on Orphan Drugs, Vol. 4, No. 3, 03.03.2016, p. 255-267.

Research output: Contribution to journalArticle

@article{5b9dda21cd2040bba14eff2b2613b6b1,
title = "Multidisciplinary management and the future of treatment in cholangiocarcinoma",
abstract = "Introduction: Cholangiocarcinoma is an often lethal and relatively rare cancer that arises from the epithelial lining of the biliary tree. Disease can arise throughout the liver, at the confluence of the right and left main hepatic ducts, or as the common bile duct runs toward the ampulla of Vater. Cholangiocarcinoma has a distinct geographic variability with the greatest incidence in the Far East. Worldwide, the incidence of cholangiocarcinoma appears to be increasing.Areas covered: In this review, a comprehensive search of the peer-reviewed literature is completed to provide an update regarding the diagnostic adjuncts, clinical management, and areas of active research for this disease. There are no reliable screening tools available for clinical detection. Surgery is the only chance for cure. Chemotherapy is often used in the adjuvant setting or in patients with unresectable disease, though outcomes are generally poor. Newer approaches that include hepatic artery-based therapies and image guided radiation therapy appear to provide limited survival benefit.Expert opinion: Maximizing survival following a diagnosis of cholangiocarcinoma relies on a multidisciplinary team of experts in medical oncology, radiation oncology, surgical oncology (principally hepatopancreatobiliary surgeons), and interventional radiology.",
keywords = "adjuvant therapy, Cholangiocarcinoma, neoadjuvant therapy, stereotactic body radiation therapy",
author = "Richard Burkhart and Daniel Laheru and Herman, {Joseph M.} and Pawlik, {Timothy M.}",
year = "2016",
month = "3",
day = "3",
doi = "10.1517/21678707.2016.1130618",
language = "English (US)",
volume = "4",
pages = "255--267",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Multidisciplinary management and the future of treatment in cholangiocarcinoma

AU - Burkhart, Richard

AU - Laheru, Daniel

AU - Herman, Joseph M.

AU - Pawlik, Timothy M.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Introduction: Cholangiocarcinoma is an often lethal and relatively rare cancer that arises from the epithelial lining of the biliary tree. Disease can arise throughout the liver, at the confluence of the right and left main hepatic ducts, or as the common bile duct runs toward the ampulla of Vater. Cholangiocarcinoma has a distinct geographic variability with the greatest incidence in the Far East. Worldwide, the incidence of cholangiocarcinoma appears to be increasing.Areas covered: In this review, a comprehensive search of the peer-reviewed literature is completed to provide an update regarding the diagnostic adjuncts, clinical management, and areas of active research for this disease. There are no reliable screening tools available for clinical detection. Surgery is the only chance for cure. Chemotherapy is often used in the adjuvant setting or in patients with unresectable disease, though outcomes are generally poor. Newer approaches that include hepatic artery-based therapies and image guided radiation therapy appear to provide limited survival benefit.Expert opinion: Maximizing survival following a diagnosis of cholangiocarcinoma relies on a multidisciplinary team of experts in medical oncology, radiation oncology, surgical oncology (principally hepatopancreatobiliary surgeons), and interventional radiology.

AB - Introduction: Cholangiocarcinoma is an often lethal and relatively rare cancer that arises from the epithelial lining of the biliary tree. Disease can arise throughout the liver, at the confluence of the right and left main hepatic ducts, or as the common bile duct runs toward the ampulla of Vater. Cholangiocarcinoma has a distinct geographic variability with the greatest incidence in the Far East. Worldwide, the incidence of cholangiocarcinoma appears to be increasing.Areas covered: In this review, a comprehensive search of the peer-reviewed literature is completed to provide an update regarding the diagnostic adjuncts, clinical management, and areas of active research for this disease. There are no reliable screening tools available for clinical detection. Surgery is the only chance for cure. Chemotherapy is often used in the adjuvant setting or in patients with unresectable disease, though outcomes are generally poor. Newer approaches that include hepatic artery-based therapies and image guided radiation therapy appear to provide limited survival benefit.Expert opinion: Maximizing survival following a diagnosis of cholangiocarcinoma relies on a multidisciplinary team of experts in medical oncology, radiation oncology, surgical oncology (principally hepatopancreatobiliary surgeons), and interventional radiology.

KW - adjuvant therapy

KW - Cholangiocarcinoma

KW - neoadjuvant therapy

KW - stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84959488873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959488873&partnerID=8YFLogxK

U2 - 10.1517/21678707.2016.1130618

DO - 10.1517/21678707.2016.1130618

M3 - Article

AN - SCOPUS:84959488873

VL - 4

SP - 255

EP - 267

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 3

ER -